Further experiment will be required to determine if the levels of EHMT1, EHMT2 and H3K9 methylation at promoters of ISGs correlate with the responsiveness of CML patient to interferon treatment. This evidence concerns the gene EHMT1 and chronic myelogenous leukemia, BCR-ABL1 positive.